Patient P-01865

Synthetic patientNBL-101 · Day 111 · 45–54 · M · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 No meaningful change — Dietary Support Protocol NP-02
Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 67 ME-01 recommended — Monitoring Escalation ME-01
Day 68 Patient accepted — Started ME-01 in the companion
Day 71 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days

Toxicity+12
Nutritional resilience-11
Inflammatory activity+10
GI instability+6
Treatment adherence+6

What helped?

Dietary Support Protocol NP-02Day 31
Result: no meaningful change
Monitoring Escalation ME-01Day 67
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Drug metabolism and exposure ↑95
- DNACYP2D6 poor metabolizer → higher exposure
- DNADPYD *2A → slower clearance
- BloodToxicity index 53
Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
- WearableSleep 4.4 h, below personal baseline
Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 61
- WearableHRV 19 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 30/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓45
- WearableResting HR 74 bpm
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Poor metabolizer
Higher exposure at standard dose
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3.2 · butyrate capacity 30/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 21 ms
Sleep: 5.1 h
Steps: 6,198
Resting HR: 73 bpm

Daily log: GI score 62, nutritional resilience 35, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01804	20%	S19	AD-05	improved	61
P-01708	31%	S07	CR-01	improved	59
P-01835	30%	S17	CR-01	improved	56
P-01388	29%	S17	CR-01	improved	59
P-01696	29%	S20	CR-01	improved	59
P-01371	28%	S06	CR-01	improved	63
P-01877	28%	S01	CR-01	improved	67
P-01442	26%	S13	CR-01	improved	61
P-01430	20%	S05	CR-01	improved	54
P-01342	19%	S11	DT-01	improved	48
P-01393	56%	S14	GI-04	improved	53
P-01364	55%	S14	GI-04	improved	49